Cargando…

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia

Detalles Bibliográficos
Autores principales:	Joe, Soohyun, Ahn, Joonho, Choi, Youngmin, Lee, JungSun, Park, Jangho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616329/ http://dx.doi.org/10.1093/ijnp/pyw041.393

Ejemplares similares

Characterising the evolution of antipsychotic polypharmacy and clozapine prescribing patterns in schizophrenia patients during psychiatric hospitalisations
por: Lagreula, J., et al.
Publicado: (2022)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
por: Yazici, Esra, et al.
Publicado: (2017)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

PM387. A preliminary study of antipsychotics polypharmacy among schizophrenia patients who admitted to national mental hospital
por: Han, Jaewook
Publicado: (2016)

Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
por: Fisher, Maxine D, et al.
Publicado: (2014)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
por: Kaikoushi, Katerina, et al.
Publicado: (2021)

Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy
por: Kim, Hee-Yun, et al.
Publicado: (2014)

Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS)
por: Mandarelli, Gabriele, et al.
Publicado: (2022)

PM441. Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
por: Vera, Gabriel Selva, et al.
Publicado: (2016)

Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients
por: Lassen, Stine, et al.
Publicado: (2023)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment
por: Repo-Tiihonen, Eila, et al.
Publicado: (2012)

The Prevalence and Factors Associated With Antipsychotic Polypharmacy in a Forensic Psychiatric Sample
por: Farrell, Christian, et al.
Publicado: (2020)

Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation
por: Lagreula, Juliette, et al.
Publicado: (2022)

PM379. Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics
por: Lin, Shih-Ku
Publicado: (2016)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
por: Yamanouchi, Yoshio, et al.
Publicado: (2015)

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
por: Ijaz, Sharea, et al.
Publicado: (2018)

Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study
por: Patrichi, Bogdan, et al.
Publicado: (2021)

PM524. VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics
por: Kim, Yongku, et al.
Publicado: (2016)

The Therapeutic Relationship and Adherence to Antipsychotic Medication in Schizophrenia
por: McCabe, Rosemarie, et al.
Publicado: (2012)

Antipsychotic treatment and cognitive function in patients with schizophrenia
por: Tumova, M. A., et al.
Publicado: (2023)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

PM390. Comparison of Fast Versus Slow Strategy in Switching Schizophrenia Patients to Aripiprazole from Other Antipsychotics
por: Hwang, Tzung-Jeng, et al.
Publicado: (2016)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis
por: Ayenew, Wondim, et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_162smm8o21a29n35qvn78ki5cn